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Introduction 34 DYT1 (dystonia 1 protein) early-onset isolated dystonia (DYT1 dystonia) is a rare hereditary form of 35 dystonia. It follows a pattern of autosomal dominant (AD) inherited movement disorder without other 36 neurological symptoms, signs, and secondary causes. It often begins in childhood and adolescence (< 37 28 years old) and the symptom commonly starts from lower limbs and frequently propagates to other 38 This is a provisional file, not the final typeset article body regions when the disease progresses (1) . The disease frequency in the Ashkenazi Jewish 39 population is calculated to be 1:3000-1:9000 while it is approximately five times lower in the non-40
Jewish population (2) . There is no known frequency in Taiwan-based population so far, even not 41 available in Asia area. DYT1 dystonia is a severe form of primary torsion dystonia with a penetrance 42 rate around 30~40% (3). This disease has a strong hereditary predisposition but lacks a distinct 43 neuropathology. In isolated dystonia, cognition and intellectual abilities remain intact despite the 44 presence of significant movement abnormalities (4). 45
Many patients diagnosed as DYT1 dystonia is originally caused by a mutation in the TOR1A gene that 46 locates at chromosome 9q34.11 and encodes TOR1A, an ATP-binding protein. A three-base pair 47 deletion (c.907_909delGAG, p.E303del, rs80358233) resulting in loss of a glutamic acid residue in the 48 TOR1A protein is identified in most affected individuals (5). The TOR1A protein can be found in the 49 endoplasmic reticulum and the nuclear envelope of most cells, including those of the central nervous 50 system (CNS). The molecular and cellular processes in which TOR1A is involved include the 51 interactions between cytoskeleton and membrane and the important functions of endoplasmic 52 reticulum and nuclear envelope (6). However, the function of TOR1A and how TOR1A gene 53 pathogenic variants lead to dystonia remains largely unknown. Moreover, the markedly decreased 54 penetrance poses a momentous challenge for diagnostic testing and genetic counseling, but also 55 provides strong viewpoint for the existence of additional genetic modifiers which influence penetrance 56 and variability of the disease (7). 57
Here, we report a boy who first exhibited waddling gait followed by fast development of typical 58 dystonia. We surveyed the patient's candidate genetic alterations first and found a deletion of residue 59 303 glutamic acid in the TOR1A (E303del). Beyond GAG-deletion, we initially screened for protective 60 TOR1A (D216H) and pathogenic TOR1A (F323_Y328del and F205I) (8,9) variants, but the results 61 were all normal alleles in the case. Then, we targeted the variants from the major binding partners of 62 TOR1A, including TOR1AIP1 and 2 or HSPA8 (10,11), but the variants from the TOR1AIP1 gene 63
have high allele frequency in the dataset which implies that they are less likely as modifiers in our case. 64
Therefore, we performed whole exome sequencing (WES) among the patient, his parents, and two 65 additional AD carriers to find the candidate variants. The result of WES analysis revealed three single 66 nucleotide variants (SNV) from the SYNE2 gene (c.1721T>C (p.I574T), c.12001T>C (p.W4001R), 67 c.12002G>A (p.W4001Ter)) and we propose that these variants may link to earlier disease onset in 68 this patient. 69
Methods

70
DNA Samples from the Patient and Family Members 71
Total 10 individuals, including 1 patient and 9 family members, were investigated in the study. After 72 acquiring written informed consent from all individual participants included in the study, the genomic 73 DNA were extracted from blood leukocytes using MagPurix ® automated DNA extraction system. 74
Detailed clinical information was obtained from corresponding clinicians and medical records. 
Results
100
Clinical Observations 101
The patient, without any major disease history in the past, had an initial presentation of waddling gait 102 at 7 years old and the symptom progressed to limbs tremor within a few months. He is the only one 103 affected with dystonia in the family. The other family members are all free from dystonia related 104 neurological disorders. At the early phase of disease, limbs tremor, pronation of the upper limbs and 105
waddling gait were noticed in full consciousness while symptoms faded away during sleep. Cognition, 106 communication and mental acuity were all preserved. Over time, head tilt, scoliosis, kyphosis, 107
repetitive and active twisting of limbs appeared sequentially. He showed poor response to medical 108 treatments and refused to receive advanced deep brain stimulation because of surgery risks. Five years 109 after the first exhibition of symptoms and signs, the patient showed generalized and profound muscle 110 twisting and contraction, including dysarthria and dysphagia. The patient presents sustained 111 opitoshtonous-like posture and needs full assistance in his daily routines. 112
Examination of Known Dystonia-Associated Mutations 113
Initial screening for known childhood-onset mutations on dystonia-associated genes TOR1A, THAP1, 114
and ataxia-associated gene FXN identified a mutation of three-base pair deletion (c.907_909delGAG) 115
in the patient's TOR1A gene. This mutation has been previously reported to result in a pathogenic 116 TOR1A (E303del) variant with an in-frame variant of Glu deletion (13). The patient's THAP1 and 117
FXN genes are both normal alleles. 118
Additional screening in the core family members revealed that TOR1A (E303del) is also present in the 119 genome of the patient's father, but neither in his mother nor in sibling. This finding demonstrates that 120 TOR1A (E303del) is originated from inheritance rather than de novo (Figure 1A, 1B) . Notably, the 121 patient and his core family members do not carry the protective dystonia-associated SNV (c.646G>C, 122 p.D216H, rs1801968) on the TOR1A gene (14) (Figure 1C, 1D) . This observation shows that the 123 difference of symptom presentation between the patient and his father is not due to the protective role 124 This is a provisional file, not the final typeset article of TOR1A (D216H). Moreover, an expanded survey in other close family members further identified 125 that the patient's aunt and the first son of the aunt as asymptomatic carriers of TOR1A (E303del) 126 (Figure 1A, 1B) . These results collectively indicate that TOR1A (E303del) is insufficient to drive 127 dystonia in this family. 128
Screening for Dystonia-Associated TOR1A Gene (c.907_909delGAG) Candidate Modifiers 129
All variants from TOR1A gene among the five WES data 130 WES was performed on the patient (subject 1) and three other TOR1A (E303del) carriers in the family 131 to explore potential modifiers. Exomes of the patient's mother (subject 2), who is neither a TOR1A 132 (E303del) carrier nor symptomatic, was also examined as a contrast. While additional variants were 133 found within the TOR1A gene of the mother, the father (subject 3), and the aunt (subject 6), including 134 variants: C>T within promoter region (rs13300897), c.246G>A (p.A82A, rs2296793), and C>A on 3'-135 UTR (rs1182) (15,16), the patient and the first son of the aunt (subject 9) only have one genome variant 136
TOR1A gene (c.907_909delGAG) in their TOR1A locus, which is pathogenic ( Table 1) . 137
Expand the search outside the TOR1A locus 138
We devised the following workflow to identify candidate genome variants from the five WES data 139 systemically (Figure 2) . After removing synonymous SNV, exonic genome variants are catalogued 140 into three groups: (1) de novo mutation (de novo)--the allele frequency (AF) of the patient is 0.5 or 1 141 while all the other family members are 0; (2) autosomal dominant inheritance (AD)--the AF of the 142 patient is 0.5 or 1 while the mother is 0.5 or 1 and the rest of the family members are 0; (3) autosomal 143 recessive inheritance (AR)--the AF of the patient is 1 while the mother is 0.5 or 1, the father is 0.5, 144
and both the aunt and the first son of the aunt are either 0 or 0.5. Subsequently, variants without clinical 145 significance, predicted as tolerable and benign by SIFT and polyphen-2 respectively, and having 146 sequencing depth less than 20 times were removed. With these filters, we identified 37 and 34 genome 147 variants (Supplementary Material_Table S1, S2) in the AD group and AR group respectively, and 148 none in the de novo group (Figure 2) . 149
In the 34 variants from AR group, the TTN gene (containing 8 variants) was excluded for further 150 consideration because of its repetitive sequence that may causes poor resolution on results from the 151 next generation sequencing techniques (17). The remaining genes and variants were filtered with 152 neurologic disorders and neuromuscular diseases firstly. Then, we removed the variants with AF higher 153 than 0.2 which makes them tend to be tolerable polymorphism existing in the human population. 154
Subsequently, we verified these variants by reference SNP reports and human gene database-155
GeneCards ® to review the clinical significance and publications. After critical review of clinical 156 relevancy and extensive literature search for protein-protein interaction evidences, we firstly targeted 157 on the variant, c.1721T>C (p.I574T, rs9944035) which resides in the SYNE2 gene and we found it have 158 been previously linked to Emery-Dreifuss muscular dystrophy (EDMD) in human disease (18). 159
Protein-protein interaction between SYNE2 and TOR1A 160
Notably, proteins encoded by the SYNE2 gene (SYNE2) and TOR1A gene (TOR1A) physically interact 161
with each other at the outer nuclear membrane (19). This finding suggests a potential genetic interaction 162 between these genome variants in our patient. Thus, we validated the SYNE2 gene (c.1721T>C) by 163
Sanger sequencing in 10 family members and the result showed that the patient has homozygous 164 mutation while the core family members and the grandmother have heterozygous alleles, which 165 suggests its origin of inheritance. Moreover, homozygous SYNE2 gene (c.1721T>C) was not found in 166
other TOR1A gene (c.907_909delGAG) carriers within the family (Figure 3) . 167
The potential role of SYNE2 on neurologic disorders 168
The SYNE2 gene (c.1721T>C, p.I574T) is expected to result in an isoleucine-to-threonine change at 169 the amino acid 574 located within the third spectrin repeat of the SYNE2. This isoleucine appears to 170 be conserved among higher mammals, which provides an implication of the potential impact from 171
having the variant (Figure 4A, left) . Meanwhile, a great similarity of amino acid sequence between 172 SYNE1 and SYNE2 implies SYNE2 gene may have role in neurologic disorders as SYNE1 gene does 173 although no known annotation found in references yet (Figure 4B ) (20) . 174
Other hits from SYNE2 gene may simultaneously enhance the disruption of protein-protein interaction 175
In addition to SYNE2 gene (c.1721T>C), the patient has three more variants, c.12001T>C (p.W4001R, 176 rs2792205), c.12002G>A (p.W4001Ter, rs2781377), and c.15556C>A (p.L5186M, rs10151658), 177
found in the SYNE2 coding region ( Table 2 ). The incidence of SYNE2 gene (c.15556C>A) is relatively 178 high in Taiwan (0.6628) and this common prevalence renders it likely a polymorphism rather than a 179 modifier. For SYNE2 gene (c.12001T>C) and SYNE2 gene (c.12002G>A), both mutations result in the 180 amino acid change of residue W4001 into arginine and termination, SYNE2 (W4001R) and SYNE2 181 (W4001Ter), respectively. Although this amino acid, tryptophan, is a not conserved site among higher 182 mammals (Figure 4A, right Taiwan-based population (both greater than 0.7) suggests that they are less likely as culprits in our case. 195
Since DYT1 dystonia is categorized as a CNS disease and best conceptualized as a motor circuit 196 disorder (23), we focused primarily on neurologic disorders and neuromuscular diseases to find out the 197 potential modifier variants. After advanced filtering, we propose that SYNE2 (I574T) could be the 198 candidate variant initially. SYNE2 gene is associated with EDMD, which is a condition that primarily 199 affects skeletal muscles. The earliest features of EDMD are joint contractures, which restrict the 200 movement of certain joints and usually become noticeable in early childhood (24). The most striking 201 and intriguing finding is TOR1A and SYNE2 physically interact with each other and exert vital 202 biologic functions (19). The TOR1A encoded by TOR1A gene binds the KASH domain of SYNE 203
(nesprin) and participates in linkage between nuclear envelope and cytoskeleton (Figure 5) . 204 SYNE are a family of proteins that are found primarily in the outer nuclear membrane and are part of 205 the LINC (linker of nucleoskeleton and cytoskeleton) complex (25). The SYNE2 (I574T) variant is at 206 the third spectrin repeat in SYNE2 and spectrin is an important mechanoresponsive protein shaping 207 fusogenic synapse architecture during myoblast fusion (26). Not only the SYNE2 (I574T) variant is 208 locally close to the Calponin Homology domain of SYNE2 where is a pivotal area for actin binding 209 (Figure 5) , but also the impact on a highly conserved amino acid in the third spectrin repeat suggests 210 a functional significance of this variant. Furthermore, more hits on SYNE2 (W4001R) and SYNE2 211 This is a provisional file, not the final typeset article (W4001Ter) respectively found in this case may seriously disrupt the physical interaction between 212 TOR1A and SYNE2 at the same time. Thus, we believe these three variants found within the SYNE2 213 gene may play the vital role on accelerating disease onset. 214
Saunders and Luxton elaborated how defects in LINC complex regulation by TOR1A may contribute 215
to the pathogenesis of DYT1 dystonia although the precise regulatory mechanism remains unclear (27). 216
Intriguingly, the loss of the glutamic acid residue in the C-terminal of one or more subunits of TOR1A 217 might act to disrupt the interaction with a partner protein (LAP1 or LULL1) or the closure of the ring 218 (heterohexamer) (Figure 5) and MCM3AP gene (c.305C>T, p.S102L, rs9975588) also emerged in our candidate list (Figure 2) . 231 However, these variants less likely serve as the TOR1A (E303del) modifiers due to lack of protein-232 protein interaction evidence after meticulous and broad literature search and review. Regarding the 233 limitation of this article, the basic issue is that we need more patients with TOR1A (E303del) to testify 234 our expectation whether variants in SYNE2 play a role in DYT1 penetrance. We also need functional 235 assessment in the future experimentation in mammalian species to clarify their roles and contributions 236 in the DYT1 dystonia. 237
Conclusion 238
In summary, we propose that SYNE2 variants maybe the potential modifier SNVs which could drop 239 the threshold of disease onset of DYT1 dystonia and facilitates the clinical symptoms and signs of 240 dystonia. We believe that this study provided a clue to unravel the candidate SNVs and try to find the 241 potential modifier variants from this family. Our findings not only echo the previous research 242
highlighting the KASH-SUN interaction and LINC complex regulation by TOR1A, but provide 243 knowledge for further understanding the disease origin of the DYT1 dystonia as well. We will 244
recommend the physicians to test these variants once the TOR1A gene (c.907_909delGAG) patient 245
show normal alleles within other TOR1A locus and other major binding proteins, such as SYNE2 gene 246 in this study. 247
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